Inhibitors of AChE, such as galanthamine, are used frequently in the pharmacotherapy of Alzheimer Disease: AChE is, indeed, dramatically down-regulated in the brains of patients suffering from this disease [35]. This evidence concerns the gene ACHE and early-onset autosomal dominant Alzheimer disease.